Relative efficacy and interchangeability ofvarious clobetasol propionate vehicles in the management of steroid-responsive dermatoses
- PMID: 24672120
- PMCID: PMC3964525
- DOI: 10.1016/j.curtheres.2005.06.010
Relative efficacy and interchangeability ofvarious clobetasol propionate vehicles in the management of steroid-responsive dermatoses
Abstract
Background: Topical corticosteroids have long been the cornerstone in thetreatment of steroid-responsive dermatoses. Despite the effectiveness of these formulations, there is a misperception that drugs delivered via ointments are more potent than those delivered via other vehicles. Potency, however, is a complex function of the physical and chemical properties of both the active ingredient and its vehicle. Studies have determined that newer vehicles (eg, lotions), particularly those in the super-high-potency class, not only heighten the ability of the active ingredient to penetrate skin but also are preferred by patients over ointments and creams.
Objective: This review of the literature investigates the effectiveness andtolerability of a high-potency corticosteroid lotion compared with cream or emollient cream formulations in treating moderate to severe plaque-type psoriasis and atopic dermatitis.
Methods: A literature search was conducted of US and international published clinical trials (1975 to November 2004) comparing all potencies of topical corticosteroid cream and lotion formulations using MEDLINE and the Web sites of individual dermatologic journals. No specific study designs were excluded from this search. Search terms included corticosteroid-responsive dermatoses, creams versus lotions, topical corticosteroid clinical trials, plaque-type psoriasis, atopic dermatitis, clobetasol propionate, drug bioavailability, Class I topical agents, and vasoconstriction. The primary diagnoses were moderate to severe plaque-type psoriasis and atopic dermatitis. Two unpublished clinical investigations comparing clobetasol propionate lotion 0.05% with clobetasol propionate cream 0.05% and emollient cream 0.05% in a total of 421 patients were also included.
Results: In the 20 published and 2 unpublished trials identified and reviewed, the response rates were comparable between the lotion and cream formulations. In addition, in a psoriasis study, clobetasol lotion received significantly better cosmetic-acceptability ratings compared with clobetasol cream (P < 0.05).
Conclusion: In the studies reviewed, the effectiveness and tolerability of clobetasollotion were comparable to those of clobetasol cream and emollient cream in studies in adults with moderate to severe psoriasis or atopic dermatitis.
Keywords: Class I agents; anti-inflammatory; atopic dermatitis; clobetasol propionate; cosmetic acceptability; duration of response; efficacy; plaque-type psoriasis; potency; safety; topical corticosteroids; vasoconstriction; vehicle.
Similar articles
-
Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis.J Dermatolog Treat. 2005 Aug;16(3):158-64. doi: 10.1080/09546630510041060. J Dermatolog Treat. 2005. PMID: 16096182 Clinical Trial.
-
The role of clobetasol propionate emollient 0.05% in the treatment of patients with dry, scaly, corticosteroid-responsive dermatoses.Clin Ther. 1998 Jan-Feb;20(1):26-39. doi: 10.1016/s0149-2918(98)80032-5. Clin Ther. 1998. PMID: 9522102 Review.
-
Clobetasol propionate lotion in the treatment of moderate to severe plaque-type psoriasis.Cutis. 2004 Sep;74(3):201-6. Cutis. 2004. PMID: 15499763 Clinical Trial.
-
Clobetasol propionate 0.05% lotion in the treatment of moderate to severe atopic dermatitis: a randomized evaluation versus clobetasol propionate emollient cream.J Drugs Dermatol. 2005 May-Jun;4(3):330-6. J Drugs Dermatol. 2005. PMID: 15898289 Clinical Trial.
-
Clobetasol propionate emollient formulation foam in the treatment of corticosteroid-responsive dermatoses.Expert Opin Pharmacother. 2008 Aug;9(11):2001-7. doi: 10.1517/14656566.9.11.2001. Expert Opin Pharmacother. 2008. PMID: 18627337 Review.
Cited by
-
Safety of topical corticosteroids in atopic eczema: an umbrella review.BMJ Open. 2021 Jul 7;11(7):e046476. doi: 10.1136/bmjopen-2020-046476. BMJ Open. 2021. PMID: 34233978 Free PMC article.
-
Topical Corticosteroid Therapy for Psoriasis-A Review of Clobetasol Propionate 0.025% Cream and the Clinical Relevance of Penetration Modification.J Clin Aesthet Dermatol. 2020 Feb;13(2):22-29. Epub 2020 Feb 1. J Clin Aesthet Dermatol. 2020. PMID: 32308782 Free PMC article. Review.
References
-
- Strober B.E., Washenik K., Shupack J.L. Principles of topical therapy. In: Freedburg I.M., Eisen A.Z., Wolff K., editors. 6th ed. vol 2. McGraw-Hill; New York: 2003. pp. 2319–2323. (Fitzpatrick's Dermatology in General Medicine).
-
- Stoughton R.B. Percutaneous absorption of drugs. Annu Rev Pharmacol Toxicol. 1989;29:55–69. - PubMed
-
- Valencia I.C., Kerdel F.A. Topical glucocorticoids. In: Freedburg I.M., Eisen A.Z., Wolff K., editors. 6th ed. vol 2. McGraw-Hill; New York: 2003. pp. 2324–2328. (Fitzpatrick's Dermatology in General Medicine).
-
- Piacquadio D.J. Topical corticosteroids in clinical practice: Focus on fluticasone propionate. Cutis. 1996;57(Suppl 2):4–9. - PubMed
-
- Stoughton R.B., Wullich K. Relation of application time to bioactivity of a potent topical glucocorticoid formulation. J Am Acad Dermatol. 1990;22:1038–1041. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources